Duration of effect of treatment of menopausal symptoms by oestrongen fraction.
A follow-up study of 17 menopausal patients receiving piperazine oestrone sulphate (Harmogen), the efficiency measured by the effect on plasma oestradiol levels, was conducted in two groups of patients. The first group had undergone an artificial menopause. Clinical relief of symptoms again correlated with the effect of the oestradiol levels, the duration of the effect exceeding the period of therapy by 3 months.